
Baricitinib is an oral JAK inhibitor that reduces excessive immune activity and inflammation. Depending on local approval, it may be prescribed for rheumatoid arthritis, severe alopecia areata, atopic dermatitis or selected hospitalised patients with severe COVID-19.
| Generic Name | Baricitinib |
| Strength | 4 mg |
| Manufacturer | Eli Lilly and Company |
| Packing | 7 Tablets |
| Prescribed For | Treat moderate to severe rheumatoid arthritis, severe alopecia areata, and certain hospitalized patients with COVID-19 requiring supplemental oxygen |
| Availability | In Stock |
| Shipping to | USA, UK, Australia, Canada, New Zealand, Philippines, Tunisia, France, Italy, South Korea, Albania, Romania, Hong Kong, Malaysia, Thailand, Singapore, Japan, UAE, Saudi Arabia, Qatar, Kuwait, Georgia, Mexico, and many other countries. |




Baricitinib blocks the Janus kinase enzymes JAK1 and JAK2. These enzymes transmit signals from inflammatory substances to immune cells. Blocking the pathway reduces excessive inflammation and immune activity responsible for joint, skin and hair-related symptoms.